Usage in Health Supplements Fuels Sodium Chondroitin Sulfate Market

28 August: Sodium Chondroitin sulfate is mostly used to treat cataract, osteoarthritis, urinary tract infections. It is used as a medicine to improve digestive function, lower blood sugar, enhanced liver function, and inhibit tumor metastasis. A human body produces chondroitin sulfate, a chemical in cartilage around joints in the body. It is usually manufactured from animal sources, such as shark and cow cartilage. It is often used in combination with other ingredients, including manganese ascorbate, hyaluronic acid, and glucosamine. 

 

High Demand for Product to Treat Eye Complications

Based on source, sodium chondroitin sulfate market can be segmented as bovine, swine, poultry, shark, and synthetic. The bovine segment is further segmented into nutraceuticals, pharmaceuticals, animal feed, personal care & cosmetics, and others. Bovine segment accounted for the largest segment in 2018 due to its usage in various applications including nutraceuticals, animal feed, and pharmaceuticals.  A byproduct of beef industry is bovine cartilage and it is generated on a large scale around the world. For human consumption, cattle byproducts are used in various parts of the world. As a source for producing sodium chondroitin sulfate, these factors have prompted manufacturers to opt for bovine.

Owing to its ability to treat eye complications, arthritis, and heal wounds, shark derived chondroitin sulfate is generally used in pharmaceutical sector. A factor that is posing a challenge to the growth of chondroitin sulfate market is that sharks are endangered species and it is prohibited to harm the sea creatures. However, sodium chondroitin sulfate retrieved from shark is used due to its ability to treat people infected with arthritis, intestine inflammation, and HIV, which is fueling the growth of the sodium chondroitin sulfate market.

Synthetic chondroitin is manufactured using a two-stage fermentation-based process. The occurrence of adulteration and contamination is reduced as the process excludes the use of animal cartilages. This also results in the extraction process becoming less complicated leading to low production cost. 

Market Insights

Factors such as increasing prevalence of arthritis among geriatric population and increasing rate of obesity has led to increased consumption of joint health supplements, which is driving the demand for sodium chondroitin sulfate. Joint health benefits and clinical efficacy are major factors promoting the market growth. Pharmaceutical grade sodium chondroitin sulfate is being increasingly used to cure osteoarthritis driving industry growth. Manufacturers and raw material suppliers have numerous opportunities to supply quality and uniform products through auditable supply chain.

Some of the leading companies of the sodium chondroitin sulfate market are Qingdao Wan tulmin Biological Products Co. Ltd.; TSI Group Ltd.; BRF; Bioiberica S.A.U.; HeBei SanXin Industrial Group; Sigma-Aldrich, Inc.; Bio-gen Extracts Private Limited; Sino Siam Biotechnique Company Limited; ZPD; and SEIKAGAKU CORPORATION. 

Rising Preference for Plant Based Products Spurs Aromatherapy Carrier Oil Growth

4 August 2020: The global aromatherapy carrier oil market is expected to grow significantly on account of increasing preference for plant extracted products. Aromatherapy carrier oils are vegetable oils that are extracted from plants, cold-pressed, and are processed naturally. They possess natural and nutritional healing properties that are used as substitutes to pharmaceutical products such as tablets and medicated topical products. Increasing popularity of using natural products in wellness and beauty sector is another factor propelling the demand for carrier oils. Another factor fueling the growth of the market is using aromatherapy carrier oil reduces the usage of harmful chemical products. These oils also have applications in personal care products.

Aromatherapy helps in treating several conditions as it is considered an alternative to medicinal therapy. It provides treatment for various diseases such as skin-related problems, pain, digestive disorders, cardiovascular disorders, cold & cough, immune disorders, insomnia, anxiety, respiratory disorders, and wounds.

Skin Issues Promote Product Usage Boosting Segment Growth

On the basis of application, the aromatherapy carrier oil market is segmented into cosmetic, personal care, food and beverage, and medical. In 2018, the cosmetic segment accounted for the largest share of the market. The growth of the segment is due to rising incidences of skin problems. Other applications of carrier oils include cosmetics for skin for scar management and for hair care to strengthen hair, reduce itching, and control dandruff.

In 2018, medical segment accounted for a significant share of the market as these products are effective in treating chronic pains. Hence, due to their high potency and health benefits with negligible adverse effects, these products are widely replacing the most conventional medications. The personal care segment is expected to witness a lucrative growth over the next few years due to introduction of natural cleaning agents. Household products and cleaning agents are increasingly being used for personal care applications owing to their antiseptic and antibacterial properties.

Market Insights

Increasing preference for plant derived products is a major factor propelling the growth of the industry. Carrier oils are naturally produced and have dietary and natural healing characteristics. They also act as alternatives to pharmaceutical products such as topical medicines and pills. Consumer preference for natural products in the form of moisturizers, creams, soaps for skin care and as toiletries, and insect repellents is increasing with increasing disposable incomes. 

Major manufacturers of aromatherapy carrier oil are increasingly inclined to adopt strategic initiatives such as mergers & acquisitions, new product development, and geographic expansion. Some of the leading companies in the aromatherapy carrier oil market are Rocky Mountain Oils; Edens Garden; Plant Therapy Essential Oils; FLORIHANA; Falcon Essential Oils; and Moksha Lifestyle Products.

High Demand from Food & Beverage Industry Spurs Gum Arabic Growth

30 June 2020:  Gum arabic is also known as meska, acacia gum, or chaar goond/ gund. Gum arabic is a natural emulsifier derivative from hardened sap obtained from two species of the acacia tree Vachellia seyal (Acacia seyal) and Senegalia senegal (Acacia senegal). The acacia trees are mainly found in the Indian subcontinent and the west coast of Africa. Gum arabic is an adaptable emulsifier used in various industries such as pharmaceuticals, food and beverages, textiles, inks, paints, ceramics, and paper. The gum is sticky and amber in color. 

Acacia Senegal Source Type Led the Global Market: 

On the basis of source type, the gum arabic market is classified into Acacia Seyal and Acacia Senegal. The Acacia senegal led the global gum arabic market in 2018. The tree is native to eastern India, Africa, and Sudan. Acacia senegal is known to yield in all kinds of seasons regardless of soil texture and climatic conditions. 

They are drought-tolerant which makes them appropriate to grow in the drier parts of the world. These trees yield the largest quantity of high quality gum when they are unhealthy. In fact, the yield and quality diminishes with improved culture methods. The major applications of this form of gum comprise of uses as essential oil, medicine, fuelwood and timber, a soil improver, for intercropping, and as an ornamental tree of the world. Furthermore, Acacia seyal is anticipated to develop as the fastest growing sector by source in the years to come. This tree is particularly found in numerous parts of Africa and is characteristic of the Nile region.

The variant is tolerant to high pH, periodic flooding, and salts, and has developed typical molecular mass of gum associated to that of Acacia senegal. These trees produce much darker gum than those produced by the senegal variants and the gum holds inferior functional characteristics. Though Acacia senegal is the key choice to yield greater quality gum, Acacia seyal is a fast expanding sector owing to it being comparatively inexpensive.

Market Insights

The market is segmented by numerous growth initiatives such as mergers and acquisitions, investment in research and development, and online sales. Manufacturers are also focusing on technological innovations, novel product launches, and capacity expansions to estimate future and existing demand patterns. Major trend players in the market are forming planned partnerships to strengthen and build their network of high-quality raw material suppliers. 

Some of the key players effective in the gum arabic market are Nexira; Gum Arabic Company; Kerry Group; Agrigum International Limited; Tic Gums Inc.; Farbest Brands; Ashland Inc.; Archer Daniels Midland Company; Prodigy NIG Limited; and Hawkins Watts.

Good Compressibility Fuels Demand of Superdisintegrants in Oral Drug Delivery

14 July 2020: Superdisintegrants is a type of excipient used for the tablet-based drug delivery in the pharmaceutical industry. Superdisintegrants are also added when solid dosage form drugs such as tablets or pills disintegrate after they are submerged in liquid. Good compressibility, poor solubility, good mouth feel, and good compatibility with other excipients are some of the useful properties of superdisintegrants. Superdisintegrants products are usually in the form of tablets, capsules, and pills due to high demand for orally delivered medicines among consumers. 

Crospovidone Ability to Stabilize Amorphous State Of Drugs Promote Segment Growth

Based on product, the superdistintegrants market is segmented into croscarmellose sodium, crospovidone, sodium starch glycolate, ion exchange resin, and others. In 2016, Crospovidone accounted for the largest share of the segment due to rapid solidification rate and inhibition of drug recrystallization. Crospovidone also has the characteristics to stabilize the amorphous state of drugs and has excellent dissolution and disintegration property, which is usually used to enhance the preparation of capsules, granules, and tablets. These factors contribute in boosting the growth of crospovidone segment.

Locust bean gum, gellan gum, and Isapghula husk, are some of the natural superdisintegrants that are expected to witness rapid growth over the next few years. Natural superdisintegrants have instant swelling characteristics due to its high hydrophilic nature and when they come into contact with water it results in rapid disintegration of tablets. Apart from these natural superdisintegrants, researchers are continuously inclined to investigate novel disintegrating agents. Products such as chitosan, modified tapioca starch, chitin, cross-linked carboxymethylguar, polymerized agar acrylamide, and xylem, have been used for testing modified natural products.

Market Insights

Increasing geriatric and pediatric population, growth in the generic drugs market, and development of new superdisintegrants for the pharmaceutical industry are driving the growth of the market. Research and the developments made in the pharmaceutical and the healthcare industry are also boosting the growth of the market. In Organization for Economic Co-operation and Development (OECD) countries, pharmaceuticals now account for about 20% of total health spending; among the top pharmaceutical spender out of the OECD, Canada is at the top.

Due to presence of large number of companies, the global superdisintegrants market is fragmented in nature. Mergers, acquisitions, and regional expansion are the key strategic undertakings of these companies to increase their market share during the forecast period. 

Some of the leading companies operating in the superdisintegrants market are Ashland Global Holdings Inc.; BASF SE; The Dow Chemical Company; Roquette Frères S.A.; FMC Corporation; DFE Pharma; Huber Corporation; and Nippon Soda Co., Ltd. 

New Product Development to Spur Contraceptives Demand

23 June 2020: Contraception is a deliberate prevention of pregnancy by interfering with the normal procedure of fertilization, ovulation, and implantation by using drugs, barriers, surgical techniques, or medical devices. Development of products such as vaginal rings, self-administrative contraceptive injections, sub-dermal contraceptive implants, non-surgical permanent contraception devices, etc. is the emerging trend in the market. The contraceptives products are in the market for more than 50 years and are mainly used by 100 million women worldwide. 

Product Insights: 

The major product variants of the contraceptives market include Contraceptive Drugs (Topical, Contraceptive Pills, and Injectables), and Contraceptive Devices, (Vaginal Implants, Female Condoms, Male Condoms, Diaphragms, Subdermal Implants, IUDs (Hormonal IUD, and Copper IUD) and Sponges). 

The Male and female condoms, subdermal implants, sponges, vaginal implants, IUDs, and diaphragms are significant devices and estimated to account for the major share of the market in terms of revenue. The growth of this segment is attributed to the increase in the consciousness level about the sexually transmitted disease (STD) and efficiency of condoms to avoid the infections, including HIV.

The most accepted form of long-acting reversible contraception comprises intrauterine devices (IUDs). The intrauterine devices (IUDs) sector is one of the largest shares of the market on account of increasing demand in the Asia Pacific and Europe region. The growing number of gynecologists advising for these devices for contraception is anticipated to propel this segment over the forthcoming period. The Mirena, a hormonal IUD, is extensively used in North America and is anticipated to sustain the growth of the contraceptives market. 

Market Insights: 

Competition in the contraceptive industry is anticipated to grow moderately in the forthcoming period. The contraceptives making companies are under constant pressure to introduced technologically advanced and new products.

In order to withstand the market, these companies accept numerous strategies such as expansions, acquisitions, new product development, mergers, and joint ventures, among others. For example, in July 2018, the Government of India introduced an app “Antararaj” in the states of India. The app will allow users to track the usage of contraceptive services, thereby also reducing the chances of drop-outs.

Leading players operating in the contraceptives market include Teva Pharmaceutical Industries; Pfizer Inc.; Merck & Co; Reckitt Benckiser Plc; Church & Dwight; Mayer Laboratories; Actavis plc; Cooper Surgical; and The Female Health Company.

Extensive Usage in Treatment of Cancer to Boost the Growth of Opioids

25th Feb 2020: Opioids are psychoactive compounds that can occur naturally or can be made in the laboratory. Opioids act on opioid receptors on nerve cells in the body or brain and relieve pain. They are generally used as pain reliever and anesthetics and are safe to use in smaller, prescribed amounts for short period of time. 

Pain Relief Segment to Contribute Substantial Demand to the Market

On the basis of application, the market is classified into anesthesia, pain relief, diarrhea suppression, de-addiction, and cough suppression. The pain relief sector dominated the market on account of high usage in pain management treatments.

On the other hand, opioids usage for pain management is also anticipated to decline on account of the new regulatory guideline by the Centers for Disease Control and Prevention (CDC). According to the new rule, medical professionals are advised to prescribe non-opioid therapy for chronic pain and opioids only for active cancer, end-of-life care, and palliative.

Market Insights: 

Key companies are concentrating on increasing their business in different regions to increase their market share in the opioids market. For example, Purdue Pharma is entering rapidly into Latin America, Asia, and the Middle East and Africa. The key players are organizing awareness programs where doctors are advised to recommend painkillers to support patients overcome opiophobia.

To decrease the dependence rate on opioid, companies are introducing generic versions of their formulations, which will minimize both the dependence rate and overprescribing. In February 2019, Mylan introduced buprenorphine and naloxone sublingual films, which in turn are non-proprietary forms of Indivior’s Suboxone. The drug got U.S. Food and Drug Administration (FDA) approval for fast commercialization.

Leading players operating in the opioids market include Allergan; Purdue Pharma L.P.; West-Ward Pharmaceuticals Corporation; Pfizer, Inc.; Janssen Pharmaceuticals, Inc.; Sun Pharmaceutical Industries Limited; and Egalet Corporation. The leading companies in the opioids are taking up partnerships, joint ventures, and mergers and acquisitions, in order to boost the inorganic growth of the industry.

Small Molecules API Segment Expected to Generate Substantial Growth Opportunities in the Forecast Period

20 Aug 2019: An active pharmaceutical ingredient (API) is mainly employed in a finished pharmaceutical product (FPP) with an aim to transport specific pharmacological actions. In addition, it can have a direct result in the cure, diagnosis, treatment, prevention, or mitigation of numerous disorders and in some situations, in correcting, restoring, or changing human physiological functions.

Cardiology segment estimated to account for the largest share in 2018

The major application variants in the active pharmaceutical ingredient (API) market include oncology, orthopedic, cardiology, CNS and neurology, pulmonology, endocrinology, gastroenterology, ophthalmology, nephrology, and others.

The active pharmaceutical ingredient (API) has found its widespread application across cardiology, CNS and neurology, oncology, and endocrinology industrial segments. Cardiology held the highest revenue share in 2018 due to growing occurrences of heart ailments across the globe. The World Health Organization (WHO) in its recent study published that Cardiovascular diseases (CVDs) particularly heart attacks and strokes, have resulted in approximately 17.5 million deaths across the globe. 

Cardiovascular diseases have increasingly been identified as a public health burden and have, therefore, fueled extensive R&D for active pharmaceutical ingredient (API) in the field. Furthermore, oncology is projected to emerge as the fastest-growing market as a result of altering lifestyle leading to rising prevalence of cancer. The active pharmaceutical ingredient (API) is majorly driven by R&D initiatives for the development of novel drugs and biomarkers. The popular APIs utilized for drug processing comprise of Bevacizumab, Rituximab, and Trastuzumab by Roche and Imatinib by Novartis.

Market Insights:

In November 2016, in France, Arrow Generiques SAS, a branch of Aurobindo Pharma Ltd., obtained rights of Calcium products and Calcium Vitamin D3 from Teva Pharmaceutical Industries Ltd.  This will allow Arrow Generiques to continue to expand its branded products’ portfolio and influence its place as a significant player in the drug market. 

Novartis AG is a global health care company that offers and develops solutions to the changing requirements of patients globally. In 2017, Novartis made 16 submissions, received six breakthrough therapy designations, and 16 approvals from the FDA. In addition, companies are accepting the strategy of collaborations and acquisitions with parallel companies in order to strengthen and improve their geographic presence in the global arena.

Key companies operating in the active pharmaceutical ingredient (API) market include AbbVie, Inc.; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim International GmbH; Merck & Co., Inc.; Albemarle Corporation; Cipla, Inc.; Mylan N.V.; Bristol-Myers Squibb Company; Dr. Reddy’s Laboratories Ltd; and Aurobindo Pharma. 

Innovation by Pharma Companies to Boost ADHD Drugs Industry

ADHD is a neurodevelopmental/ neurobehavioral brain disorder characterized by impairing and pervasive symptoms of hyperactivity, impulsivity, and inattention. Centers for Disease Control and Prevention (CDC) has defined ‘neurobehavioral’ as the way brain disturbs behavior, learning, and emotion. Scientists at the National Institute of Mental Health (NIMH) state that the factors disturbing mental illness comprise of brain injuries, drugs used during pregnancy, low birth weight, and contact with environmental contaminants such as lead, at a young age. 

High Consumer Demand to Boost Market

The major drug type variants in the market include stimulant and non-stimulant drugs. Stimulant drugs further comprise Methylphenidate, Amphetamine, Dexmethylphenidate, and Lisdexamfetamine. Non-stimulant drugs comprise Guanfacine, Atomoxetine, Bupropion, and Clonidine. 

The stimulant drug type segment accounted for the largest share in the market and will continue its dominance over the forthcoming period. The key factors that could be attributed to the growth include high demand for these drugs owing to their effectiveness in treating symptoms of this disorder. In addition, government support and ongoing clinical trials for the use of stimulants in the treatment of mental health disorders will spur the demand in the forecast period.  

In April 2016, Tris Pharma, Inc. declared the introduction of its FDA-approved ADHD tablet Dyanavel XR, that is used to treat patients 6 years and above.

Non-stimulants are anticipated to show the fastest development rate in the years to come owing to their long-term result related to stimulants. Additionally, the growing number of market players have been capitalizing on the growth of non-stimulant drugs in the market, which will likely drive the non-stimulants drug segment in the forecast period. 

Market Insights: 

In December 2015, U.S. Food and Drug Administration (FDA) gave approval to Pfizer for Quillichew ER, a chewable capsule for therapy of ADHD in patients over the age of six. This is presented in 40mg, 30mg, and 20mg formulations. Additionally, in February 2018, Lupin launched a generic form of Kapvay in the U.S, which extended its product line for the treatment of this syndrome.

Leading players operating in the attention deficit hyperactivity disorder (ADHD) market include Pfizer; Eli Lily and Company; Lupin; Johnson & Johnson Services, LLC; Shire; Prude Pharma L.P.; NEOS Therapeutics Inc; and Mallinckrodt. These key manufacturers also emphasize on numerous other business strategies, such as product developments, partnerships, technical collaborations, agreements, and capacity expansions to support their market place.

Technological Linkers Accelerating the Demand for ADCs

16th May 2019: Antibody drug conjugates (ADCs) are the most important bio-pharmaceutical drugs that are highly potent and are designed to treat cancer. These conjugates intend to aim and destroy only the cancer cells while keeping healthy cells unaffected. ADCs are the most complex molecules that are majorly composed of an antibody that is linked to a biologically active cytotoxic payload or drug. 

Technological advancements to spur the demand for antibody drug conjugates

Cleavable and non-cleavable linkers are the two types of technology in the antibody drug conjugates market and are the most prime technologies used to link cytotoxic anticancer agent’s payload. It has been projected that cleavable linkers will foresee the fastest development during the estimated time span due to the vast number of products in the pipeline and the extensive usage of linkers. 

The market witnessed the launch of two new Pfizer’s products in 2017, Bespona and Mylotarg that were accepted for the usage in the developed countries and both these products contained cleavable linkers. Additionally, Adcetrics and Kadcyla are two of the best-selling ADcs that comprise cleavable and non-cleavable linkers. The World Health Organization (WHO) stated that in 2017 the most common types of cancer were lung cancer, breast cancer, prostrate cancer, stomach cancer, skin cancer, and colorectal cancer. Rising cases of these cancers is one of the major dynamic that is surging the growth of the market. 

Antibody drug conjugates are surging in the developed economies

Cleavable linkers are majorly accelerating in North America region and its countries due to the tremendous demand for Mylotarg. Furthermore, this region is anticipated to witness the fastest growth over the forecast period because most of the cleavable and non-cleavable linkers are being highly developed in the U.S. Europe is also expected to continue its dominance due to the massive usage of ADCs coupled with immense patient awareness and well-established infrastructure of healthcare. 

Market Insights

Some of the major key players that are operating and helping the antibody drug conjugates market to accelerate are Pharmaceutical Company Limited; Seattle Genetics Inc.; F. Hoffmann-La Roche Ltd.; Takeda Pfizer Inc.; and AbbVie Inc. 

Online & Retail Pharmacies to Spur Demand for Antacids

9th May 2019: Antacids are medications that help in neutralizing the acid in the stomach to cut down on upset stomach, heartburn, acid indigestion, and sour stomach. Antacids incorporate aluminum hydroxide, magnesium carbonate, and magnesium trisilicate, which help in reducing gastroesophageal reflux disease (GERD) and some other symptoms such as belching, bloating, and nausea. 

According to a study conducted by American Gastroenterological Association that was published in the International Functional Foundation, the demand for antacids is increasing steadily in the U.S. because one-third of their population is suffering from gastroesophageal reflux disease. Furthermore, the awareness about gastroesophageal reflux disease is surging rapidly, which in return is propelling the growth of the global antacids market and is expected to spur massively during the forecast period (2019-2025).

Availability of antacids is spurring the growth of the industry

On the basis of the distribution channel, the market is bifurcated into retail, pharmacy, hospital pharmacy, and online pharmacy. Online pharmacy is projected to be the fastest growing segment in the estimated time span due to the rising awareness among consumers. In 2017, the Alliance for Safe Online Pharmacies (ASOP Global) conducted a survey, which stated that around 33% of participants from Canada purchased the medicinal prescription from an online pharmacy.

Furthermore, retail pharmacies held the largest share of the market owing to the ease in the availability and accessibility of these pharmacies. For instance, one of the most noteworthy key participants, MedPlus has around 1,400 outlets worldwide among which 50 are franchisee and 1,350 are self-owned. This is leading to greater demand for antacids as it is available all over the world. 

The digestive system diseases are strongly helping the market to extend its reach

Regionally, online pharmacies are surging tremendously in North America and is anticipated to hold the highest share of the market in the forthcoming years owing to the acceleration in the digestive disorders that is prevailing along with the awareness of antacid products. In 2017, Centers for Disease Control and Prevention(CDC) said that around 32.3 million people were diagnosed from digestive system diseases in the regions of North America and this is another reason that is fueling the growth of the market.  

Moreover, the Asia Pacific is expected to place itself in the largest and fastest growing region over the forecast period owing to the rise in the disposable income, effective treatment methods, and unmet medical needs. Additionally, the market participants are growing their investments, which is boosting the development of the antacids market tremendously.   

Rosacea Treatment- Development of Dermabrasion and Laser Therapy

30th April 2019: Rosacea is a common skin condition characterized by visible blood vessels and redness on the cheeks and nose. The signs and symptoms of rosacea are formation of red, small, pus-filled bumps, which may flare up repeatedly. Around half of the patients suffer from irritation of eyelids and redness, swelling, dryness in the eye. Other symptoms comprise of enlargement and thickening of skin on the nose (rhinophyma). The disease is mainly observed in middle-aged women having fair skin tone.

Strong Competition from Off-label Drugs

The major drug class-variants of rosacea treatment include alpha agonists, antibiotics, corticosteroids, retinoids, antihypertensive agents, immunosuppressants, and others. Antibiotics are commonly used as the first line of treatment. One of the most commonly prescribed antibiotics for rosacea is Metronidazole.

Some of the other antibiotics used in rosacea treatment comprise of erythromycin, clarithromycin, clindamycin, doxycycline, tetracycline, minocycline, azelaic acid, and sulfacetamide products are suggested in the first line of therapy. Immunosuppressants, like tacrolimus, are also used to decrease itching and inflammation by suppressing cytokines.

The alpha agonists segment is the fastest growing drug class and is anticipated to grow high in the forecast period. The key factor attributed to the growth of the market is high demand from the consumers. The alpha agonists class has two key revenue generators, namely, Rhofade and Mirvaso. Both the products are specified for rosacea-associated erythema.

Market Insights

The market is expected to face strong competition throughout the forthcoming period due to the existence of multinational establishments. Leading players operating in the rosacea treatment market include Bayer Schering AG; Allergan Plc; Nestlé S.A.; and Bausch Health Companies Inc. 

The market is driven by the expected launch of promising pipeline applicants from Sol-Gel Technologies and Foamix Pharmaceuticals. Novel product development, joint ventures, and geographical expansion are some of the important policies accepted by significant market players.

Nestlé S.A. (Galderma section) led the competitive space and is predicted to continue holding the major market share, supported by the strong commercial performances of Oracea, Mirvaso, Soolantra, and Metro Gel. In addition, Rhofade from Noritate and Allergan from Bausch are important revenue contributors.

An Effective Non-Invasive Solution for Nasal Drug Delivery

18th April 2019: Nasal drug delivery is mainly used as a treatment of local infection in the paranasal sinuses and nasal courses such as non-allergic and allergic rhinitis and sinusitis. This technique is mainly used to ease the problem of gradual absorption of drugs, degeneration before reaching the focus place, and poor bioavailability. Furthermore, it supports in resolving problems associated with the gastrointestinal (GI) tract and first-pass metabolism in the liver.

High Demand for Generic Forms of Spray Drugs to Boost Spray Dosage Form

The major dosage form-variants of nasal drug delivery technology are a drop, nasal spray, powder, and gel. The sprays segment surpassed the market due to the allergic rhinitis, increasing demand for common forms of spray drugs, and increasing incidences of infections. 

In 2016, as per the Healthy People 2020, made available by Office of Disease Prevention and Health Promotion, morbidity exists and differences in asthma mortality, particularly in middle-class populations and minority, causes people to tend more toward profitable choices.

In addition, Nasal sprays are followed by nasal drop segment and is anticipated to be the highest growing dosage form sector over the forthcoming period owing to product success rate for this treatment and affordability. 

Moreover, increasing patient compliance and inclination toward self-administration are likely to increase the growth of this segment. Furthermore, the accessibility of several numbers of drops in the market is anticipated to contribute to the nasal drop growth in the future. 

Market Insights

The market is expected to face strong competition throughout the forthcoming period due to the existence of multinational establishments. Novel product development, joint ventures, and geographical expansion are some of the important policies accepted by significant market key players. 

For example, Opti Nose, Inc., in 2016, declared a pipeline scheme to monitor nose-to-brain application, which is sponsored by Research Council of Norway for curing narcolepsy of Orexin-A using Opti Nose Bi-Directional Breath Powered delivery technology.

North America will observe robust development over the forecast period owing to established economies in the region and consumer consciousness about nasal products.

Leading players operating in the nasal drug delivery technology market include AstraZeneca PLC; GlaxoSmithKline PLC; B.F. Ascher & Company, Inc.; Becton, Dickinson and Company; Pfizer, Inc.; Opti Nose, Inc.; Cadila Pharmaceuticals Ltd.; Douglas Pharmaceuticals Ltd.; Promius Pharma, LLC; PendoPharm, Inc.; NAVEH Pharma Ltd and ENT Technologies Pty. Ltd.

Plasma Protein Therapeutics to Treat Multiple Respiratory and Neurological Disorders

Monday, 19 February 2019: Plasma proteins are likely to be used in replacement therapies to treat deficiency of coagulation factor in terms of hemostasis. This deficiency can occur due to autoimmune disorder or it can be genetic. It can also occur as complication of cancer. Hemostasis can be defined as a process in humans, which can cause bleeding to stop. In this process, the blood is expected to coagulate from liquid form to gel. Lack of coagulation factor can lead to blood loss during accidents or medical procedures. Plasma protein can balance the deficiency and support coagulation of blood.  

Albumin to Support Diagnosis of Diabetes

Major product variants of plasma protein therapeutic are immunoglobulin, albumin, and factor viii. Albumin segment is expected to witness significant market share in coming years attributed to increasing use in diagnostic procedure for hypoalbuminemia. Hepatitis B and liver cirrhosis are likely to cause medical sign called hypoalbuminemia in humans. Rising cases of disease across the globe is anticipated to propel product demand in coming years. Most companies and research institutes are investing in research activities to find advanced applications of the product in healthcare sector. For instance, a group of scientists at National Chemical Laboratory in India recently discovered that measuring level of free albumin and albumin attached to glucose molecules in blood can help diagnose diabetes in better manner. The level of glucose bound hemoglobin can efficiently explain diabetic condition in individuals.    

Market Insights

The global plasma protein therapeutic market is anticipated to reach USD 33.15 billion by 2025, according to a report by Grand View Research, Inc. Advent of novel products offering easy plasma sample extraction technique can augment market growth. These products can also offer improved efficacy in clinical procedures and impel growth of market. Rising demand for albumin and increasing use of immunoglobulin in developed countries can drive the market in coming years. Manufacturing companies are expected to focus on development of advanced products to treat various neurological disorders including post-polio syndrome, Myasthenia gravis, and neuropathic pain. High demand for immunoglobulins, protein mainly derived from plasma cells to neutralize pathogens such as viruses and bacteria can stimulate market growth during the forecast period (2014 to 2025).

Some of the leading companies operating in the market for plasma protein therapeutic market are Shire Plc, CSL Behring LLC, Grifols S.A., Octapharma AG, and Bayer AG.

Aromatherapy: An Effective Alternative to Traditional Medicine

12 September 2018: Aromatherapy is considered as an effective substitute for conventional medicine as it helps enhance physical and psychological health of an individual without any adverse effects. It is widely used for different purposes including pain management, skin and hair care, insomnia treatment, cold and cough treatment, scar management, relaxation, and so on.
The therapy uses all-natural products since they are non-toxic and safe to inhale. Some of these products include essential oils and carrier oils, extracted from tree leaves, flowers, roots, and stems; while the common methods of delivery include areal diffusion, direct inhalation, and topical application.

Naturally-derived Essential Oils for Better Treatment

Many people prefer natural products and methods for stress management and for treating various health-related issues. Thus, major companies in the field focus on product innovation. For instance, doTERRA International, recently developed an essential oil called Copaiba to treat anxiety issues. It is extracted from resin of the copaiba tree. It can be applied directly on the skin or can be used in several cosmetic products such as creams, soaps, perfumes, and lotions.

The cold and cough application segment is predicted to register a significant CAGR during the forecast period (from 2018 to 2025). The skin and hair care segment is also likely to show lucrative growth due to rising occurrences of skin rashes, acne, and hair-related problems. In 2016, relaxation application segment accounted for the largest share owing to increasing number of individuals suffering from anxiety and stress.

Market Overview
According to Grand View Research, Inc., the global aromatherapy market is expected to attain USD 2.35 billion by 2025. Rising use of essential oils along with increasing popularity of aromatherapy can propel the market growth over the coming years. Adverse effects associated with pharmaceutical drugs are encouraging people to use natural essential oils, which is also likely to contribute toward market development. Key companies in this market include Young Living Essential Oils; Rocky Mountain Oils; Frontier Natural Products Co-op; Mountain Rose Herbs; and doTERRA International.

Read more @

https://www.grandviewresearch.com/industry-analysis/aromatherapy-market

Innovations in Psoriasis Drugs to offer Safe and More Effective Treatment

Rising cases of psoriasis along with the unavailability of precise therapies are anticipated to propel the demand for advanced drugs and therapeutic techniques. Such innovative techniques are likely to increase the efficacy and safety while curing the disease. In addition, better drugs and therapies can support controlling the spread of the disease.

Interlukin Inhibitors to Witness the Fastest Growth

Major therapeutic classes for psoriasis are interleukin inhibitors, Tumor Necrosis Factor (TNF), and vitamin D analogues. In the coming years, interleukin inhibitors are anticipated to witness the maximum growth owing to improved efficacy and safety profiles. Some of the well-known interleukin inhibitors include Taltz (ixekizumab), Siliq (brodalumab), Stelara (ustekinumab), Cosentyx (secukinumab), and Tremfya (guselkumab). On the other hand, the TNF inhibitors segment may witness a decline on account of growing adoption of IL-inhibitor drugs.

Most of the prominent companies in the field are focusing on R&D activities to introduce safer, more effective drugs for the disease treatment. For instance, a team of researchers from the University of Geneva (UNIGE) and Geneva University Hospitals recently tested a molecular inhibitor of interlukin-18 or IL-18 successfully. The encouraging results of this test, in terms of efficacy and safety, are likely to offer a new way of treatment for psoriasis, as well as several other inflammatory diseases.

Market Insights

The global psoriasis drugs market is likely to reach at USD 21.4 billion by 2022 growing at a CAGR of 9.3 % during the forecast period (from 2016 to 2022), according to a report by Grand View Research, Inc. Increasing number psoriasis patients across the globe is anticipated to be the major factor during the market demand. In addition, increasing awareness regarding the disease among people is expected to spur the market expansion.

Growing number of reimbursement guidelines for the disease treatment would also fuel the market demand in near future. availability of advanced therapeutic techniques owing to constant technological developments can further drive the market growth in the coming years. Some of the leading companies offering effective therapeutics for psoriasis are AbbVie Inc.; Novartis AG; Amgen Inc.; Eli Lilly & Company; Johnson & Johnson; and AstraZeneca.

Read more: https://www.grandviewresearch.com/industry-analysis/psoriasis-drugs-market

New Systems Enable Innovation in Clinical Trial Supplies and Design

A clinical trial supply chain is more than just logistics. As many biopharmaceutical firms are expanding their operations across the globe, various elements of the trial may experience differences based on local regulations and infrastructure. Planning and management of clinical trial supplies is a complex task. Various factors such as regulatory compliance, temperature sensitivity, and drug safety and security have a considerable impact on costs and timelines of a study. Due to this, sponsors and clinical research organizations (CROs) have started focusing on clinical trial supply management.

Agile IRT/RTSM System for Supply Managers

By way of products and services, the market comprises manufacturing, supply chain management, and storage and distribution. Supply chain management is considered to be the leading segment thanks to advancement in technology and need to control R&D costs.

In the latest Xtalks webinar, industry experts discussed the importance of Agile Interactive Response Technology/Randomization and Trial Supply Management (Agile IRT/RTSM) in clinical trials. These systems allow developments in clinical trial designs and supply chain management. As procedures become more intricate and trials become patient-centric, the implemented system for randomization and clinical trial supply is going to be extremely essential for a better clinical systems strategy. These systems offer flexibility and speed, which can support complex procedures that need quick changes.

Market Insights

According to findings of a research report by Grand View Research, Inc., the global clinical trial supplies market is expected to witness expansion at a strong CAGR of 7% during the forecast period (from 2017 to 2025). Rising number of clinical trials, along with increasing complexity in conducting these trials, is a major growth driver for the global market. In addition, rising number of biosimilar and biologics drugs in clinical trials is estimated to contribute toward global market expansion.

Some of the leading companies operating in the worldwide market for clinical trial supplies are Thermo Fischer Scientific; PAREXEL International Corp.; Biocair International Ltd.; Almac Group Ltd.; Catalent Pharma Solutions; and Sharp Packaging Services.

To get free sample report at:
http://www.grandviewresearch.com/industry-analysis/clinical-trial-supplies-market/request

New Anti-aging Therapy using Astaxanthin Promises Better Results

Astaxanthin is reddish, naturally occurring, and powerful carotenoid pigment found in particular marine plants as well as animals. Astaxanthin is present in its maximum natural concentration in wild Pacific sockeye salmon. It is also present in algae, krill, shrimp, red trout, lobsters, and crab. It is one of the best natural antioxidants. It helps fight various health problems such as fatigue, joint pain, vision issues, and skin-related issues. 

Other key functions include:

• Protecting the nervous system and cells from oxidative damage

• Supporting cardiovascular health

• Supporting immune system

• Supporting brain health

Breakthrough Anti-aging Therapy using Astaxanthin

Owing to its many benefits, astaxanthin finds application in aquaculture and animal feed, cosmetics, nutraceuticals, and others. Rising demand for anti-aging creams and products is likely to benefit the cosmetics industry as a key application segment.

The John A. Burns School of Medicine of the University of Hawaii and Cardax Inc., Honolulu-based life sciences company, recently announced the results of their study assessing the use of astaxanthin in anti-aging therapy. The astaxanthin compound CDX-085 by Cardax showed capacity to considerably enhance the expression of the gene FOX03, which has an important role in longevity.

Market Overview

According to findings of a report by Grand View Research, Inc., the worldwide astaxanthin market is estimated to showcase rapid growth during the forecast period (from 2017 to 2025), reaching a value of USD 2.57 billion by 2025. Increased awareness about various health benefits and potential uses of astaxanthin is expected to help market expansion.

In addition, due to growing geriatric population, demand for cosmetics such as antioxidant products and anti-aging creams to enhance aesthetic appeal have increased. This factor is anticipated to boost the growth of the market over the next few years.

JX Nippon Oil and Energy Corp; Heliae Development, LLC; BlueOcean NutraSciences, Inc.; Fuji Chemical Industry Co., Ltd.; EID-Parry (India) Ltd.; and Cyanotech Corp. are some of the prominent companies operating in the worldwide astaxanthin market. These major companies are implementing strategies such as using new production technologies to gain the top market position.

To get free sample report at:

http://www.grandviewresearch.com/industry-analysis/global-astaxanthin-market/request